Littérature scientifique sur le sujet « Vaginal immunization »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Vaginal immunization ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Vaginal immunization"
Parr, Earl L., et Margaret B. Parr. « Immunoglobulin G, Plasma Cells, and Lymphocytes in the Murine Vagina after Vaginal or Parenteral Immunization with Attenuated Herpes Simplex Virus Type 2 ». Journal of Virology 72, no 6 (1 juin 1998) : 5137–45. http://dx.doi.org/10.1128/jvi.72.6.5137-5145.1998.
Texte intégralJohansson, Eva-Liz, Carola Rask, Margareta Fredriksson, Kristina Eriksson, Cecil Czerkinsky et Jan Holmgren. « Antibodies and Antibody-Secreting Cells in the Female Genital Tract after Vaginal or Intranasal Immunization with Cholera Toxin B Subunit or Conjugates ». Infection and Immunity 66, no 2 (1 février 1998) : 514–20. http://dx.doi.org/10.1128/iai.66.2.514-520.1998.
Texte intégralWira, C. R., et C. P. Sandoe. « Specific IgA and IgG antibodies in the secretions of the female reproductive tract : effects of immunization and estradiol on expression of this response in vivo. » Journal of Immunology 138, no 12 (15 juin 1987) : 4159–64. http://dx.doi.org/10.4049/jimmunol.138.12.4159.
Texte intégralEriksson, Kristina, Marianne Quiding-Järbrink, Jacek Osek, Åke Möller, Stellan Björk, Jan Holmgren et Cecil Czerkinsky. « Specific-Antibody-Secreting Cells in the Rectums and Genital Tracts of Nonhuman Primates following Vaccination ». Infection and Immunity 66, no 12 (1 décembre 1998) : 5889–96. http://dx.doi.org/10.1128/iai.66.12.5889-5896.1998.
Texte intégralLivingston, Julie B., Shan Lu, Harriet Robinson et Deborah J. Anderson. « Immunization of the Female Genital Tract with a DNA-Based Vaccine ». Infection and Immunity 66, no 1 (1 janvier 1998) : 322–29. http://dx.doi.org/10.1128/iai.66.1.322-329.1998.
Texte intégralWang, Yichuan, Yongjun Sui, Jason Steel, John Morris et Jay Berzofsky. « Vaginal type-II mucosa acts as an inductive site during the generation of primary CD8+ T cell mucosal immune responses (P3186) ». Journal of Immunology 190, no 1_Supplement (1 mai 2013) : 124.4. http://dx.doi.org/10.4049/jimmunol.190.supp.124.4.
Texte intégralMedaglini, Donata, Marco R. Oggioni et Gianni Pozzi. « Vaginal Immunization with Recombinant Gram-Positive Bacteria ». American Journal of Reproductive Immunology 39, no 3 (mars 1998) : 199–208. http://dx.doi.org/10.1111/j.1600-0897.1998.tb00354.x.
Texte intégralUehling, David T., Walter J. Hopkins, Jean Jensen et Edward Balish. « Vaginal Immunization Against Induced Cystitis in Monkeys ». Journal of Urology 137, no 2 (février 1987) : 327–29. http://dx.doi.org/10.1016/s0022-5347(17)44015-8.
Texte intégralHogge, Christopher James, Sabrina Helmold Hait, Gospel Enyindah-Asonye, Zuena Mushtaq, Tanya Hoang et Marjorie Robert-Guroff. « Replicating Ad-SIV recombinant vaccines elicit mucosal humoral immunity in rhesus macaques at both rectal and vaginal sites with potential protective efficacy ». Journal of Immunology 202, no 1_Supplement (1 mai 2019) : 72.2. http://dx.doi.org/10.4049/jimmunol.202.supp.72.2.
Texte intégralHymel, Terri J., Joseph Sherman, Sandra K. Pope et Kelly J. Kelleher. « Inadequate Immunizations ». Clinical Pediatrics 32, no 3 (mars 1993) : 156–60. http://dx.doi.org/10.1177/000992289303200306.
Texte intégralThèses sur le sujet "Vaginal immunization"
Philosof, Bar. « A bacterium from the human microbiota as a vaccine vector. Efficient priming of the murine immune system by vaginal delivery of recombinant Streptococcus gordonii ». Doctoral thesis, Università di Siena, 2022. http://hdl.handle.net/11365/1216735.
Texte intégralLogerot, Sandrine. « Utilisation de l’interleukine-7 en immunothérapie chez des patients VIH-mauvais répondeurs immunologiques et comme adjuvant de vaccination muqueuse chez le macaque rhésus ». Thesis, Sorbonne Paris Cité, 2015. http://www.theses.fr/2015USPCB111.
Texte intégralHighly Active Antiretroviral Therapy (HAART) has led to significant reduction of HIV-associated mortality by maintaining an undetectable viral load and inducing progressive CD4-T cell restoration. However, some patients, defined as poor immunological responders (PIR), fail to restore their CD4 counts to 500cells/µL during treatment, a threshold considered as the protective against AIDS related or non AIDS related malignancies, opportunistic infections and cardiovascular events. Interleukin-7 (IL-7), an essential cytokine for thymopoïesis and T cell homeostasis has been used in clinical trials aimed at restoring and maintaining CD4 counts in PIR patients. The first part of my thesis project aimed at assessing the impact of IL-7 therapy on circulating HIV reservoir. In the clinical study we worked on (INSPIRE 3, Cytheris), cycles of IL-7 injections led to a significant increase of the number of circulating CD4 and CD8 T-cells, with a predominance of naïve and central memory T cell expansion. We have shown that one cycle of IL-7 injections induced a significant increase in the number of circulating infected cells 28 days and 3 months post-injections. However, despite a significant increase in the frequency of infected CD4 T-cells 28 days post-injections, we observed a significant decrease of HIV-DNA load in CD4 T-cells in the majority of patients 3 months after the therapy initiation. These data suggest a partial elimination of HIV infected cells. After the second cycle of IL-7 injections, we did not observed any change in the number or frequency of circulating infected cells, suggesting a differential impact of the two IL-7 injection cycles on the dynamics of circulating HIV-reservoir. Finally, considering that some patients developed anti-IL-7 neutralizing antibodies (Nab) after the second cycle of IL-7 injections, we looked for predictive factors of this immunogenicity and analyzed its physiological consequences in vivo. The only parameter that distinguished Nab and non-Nab patients was the extent of CD4 T-cell reconstitution during the first cycle of therapy. This suggests that a better response to IL-7 also facilitates the development of auto-antibodies to the cytokine. However, these antibodies were only transiently detectable after the second cycle of therapy. Moreover, the appearance of Nab was associated with a significant but transient decrease of thymocyte proliferation, suggesting a functional impact of these antibodies on the endogenous IL-7 function. Systemic injection of IL-7 induces circulating T cells homing from the blood into lymphoid and non-lymphoid tissues. In the second part of my thesis project, I evaluated whether this cytokine could be used as an adjuvant when sprayed on the vaginal mucosa. Ten micrograms of IL-7 directly sprayed in the vaginal tract of rhesus monkeys induced, 48h after administration, the production of a large pattern of chemokines in the vaginal chorion and epithelium. This chemokine expression was accompanied by massive homing of CD4 and CD8-T cells, macrophages, dendritic cells and NK cells in the vaginal mucosa, suggesting an increased immunological vigilance. Finally, the adjuvant potential of this cytokine was confirmed by analyzing local humoral immune response after vaginal administration of antigens 48h following IL-7 spray. In cervicovaginal washes (CVL) of treated animals, we observed a faster, stronger and longer-lasting specific IgA and IgG response than in control animals, highlighting the capacity of IL-7 to prepare the vaginal mucosa response to local antigen stimulation
Ambrose, Zandrea. « Immune control of SHIV in macaques upon mucosal infection of immunization / ». Thesis, Connect to this title online ; UW restricted, 2001. http://hdl.handle.net/1773/9290.
Texte intégralChapitres de livres sur le sujet "Vaginal immunization"
Thapar, M. A., E. L. Parr et M. B. Parr. « Effects of intravaginal and pelvic immunization on specific antibody in mouse vaginal fluid ». Dans Advances in Mucosal Immunology, 606–7. Dordrecht : Springer Netherlands, 1990. http://dx.doi.org/10.1007/978-94-009-1848-1_185.
Texte intégralUgwumadu, Austin. « General and specific infections in pregnancy including immunization ». Dans Oxford Textbook of Obstetrics and Gynaecology, sous la direction de Sabaratnam Arulkumaran, William Ledger, Lynette Denny et Stergios Doumouchtsis, 213–32. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198766360.003.0017.
Texte intégralRapports d'organisations sur le sujet "Vaginal immunization"
Chattopadhyay, Ishita, John Townsend et Saumya RamaRao. Offering progesterone contraceptive vaginal rings for postpartum women through integrated family planning and immunization services. Population Council, 2015. http://dx.doi.org/10.31899/rh9.1023.
Texte intégral